EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease

Maximilian Robert Gysan iD, Kastriot Kastrati, Svitlana Pochepnia, Helmut Prosch iD, Antje Lehmann, Silvia Lee, Andreas Renner, Christina Bal iD, Anastasia Papaporfyriou iD, Christopher Milacek iD, Lukasz Antoniewicz, Seda Metekol und 14 weitere

Journal of Clinical Medicine · 22.06.2026 · 15 (12) · 4834

DOI: 10.3390/jcm15124834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.06.2026. Verfasst von Maximilian Robert Gysan und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic autoimmune rheumatic diseases-associated interstitial lung disease (SARD-ILD) presents with varied disease courses, emphasizing the need for reliable predictors of progression. The prognostic utility of bronchoalveolar lavage (BAL) in SARD-ILD remains underexplored. The objective of this study was to evaluate the role of BAL fluid lymphocyte count in predicting disease progression in patients with SARD-ILD.

Methods

This observational study included patients with SARD-ILD undergoing BAL as part of their diagnostic workup. Disease progression was defined as either Forced vital capacity (FVC) decrease >10%, two out of the following three criteria within two years: FVC decrease of 5–10%, worsening symptoms, increased fibrosis on imaging, or any of the following: escalation of treatment, Interstitial lung disease (ILD) exacerbation, lung transplantation, or disease-specific mortality. Logistic regression identified predictors of progression. Time-to-progression was assessed using Kaplan–Meier survival curves. The optimal BAL lymphocyte threshold for predicting progression was identified using the Youden Index and the Wilcoxon method.

Results

We identified 89 patients, of whom 30 (33.7%) had progressive disease. Progressors had a significantly higher BAL lymphocyte count compared to non-progressors (31.6 ± 24.8% vs. 14.3 ± 16.5%, p < 0.001). BAL lymphocyte proportion was significantly and independently associated with disease progression (odds ratio, 1.05; 95% confidence interval 1.02–1.07; p < 0.01). A lymphocyte count above 9 percent was associated with a markedly increased risk of disease progression (odds ratio, 13.14; 95% confidence interval, 4.20–51.98; p < 0.01).

Conclusions

BAL lymphocyte count was associated with a higher likelihood of progression in SARD-ILD. BAL assessment may help identify patients at increased risk of disease progression. However, these findings should be considered exploratory and require validation in larger prospective studies and across individual SARD-ILD subtypes.

Schlagwörter

Stichwörter der Autor:innen

bronchoalveolar lavagebronchoscopyinterstitial fibrosissystemic autoimmune rheumatic diseases-associated interstitial lung disease

Autor:innen und Institutionen

  • Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.
  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria.
  • Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria.
  • Department of Medicine II, Lower Austrian Centre for Rheumatology, Karl Landsteiner Institute for Clinical Rheumatology, State Hospital Stockerau, 2000 Stockerau, Austria.

ORCID-Profile: Maximilian Robert Gysan, Helmut Prosch, Christina Bal, Anastasia Papaporfyriou, Christopher Milacek, Karolina Anderle, Ahmed El-Gazzar, Helga Lechner-Radner

Zitieren

APA

Gysan, M. R., Kastrati, K., Pochepnia, S., Prosch, H., Lehmann, A., Lee, S., Renner, A., Bal, C., Papaporfyriou, A., Milacek, C., Antoniewicz, L., Metekol, S., Kramer, M., John, L., Kargarpour, Z., Aykara, I., Weber, P., Anderle, K., Kiener, H. P., …, & Lechner-Radner, H. (2026). Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease. Journal of Clinical Medicine, 15(12), 4834. https://doi.org/10.3390/jcm15124834

Vancouver

Gysan MR, Kastrati K, Pochepnia S, Prosch H, Lehmann A, Lee S, et al. Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease. Journal of Clinical Medicine. 2026;15(12):4834. doi:10.3390/jcm15124834

BibTeX
@article{Gysan2026,
  author = {Gysan, Maximilian Robert and Kastrati, Kastriot and Pochepnia, Svitlana and Prosch, Helmut and Lehmann, Antje and Lee, Silvia and Renner, Andreas and Bal, Christina and Papaporfyriou, Anastasia and Milacek, Christopher and Antoniewicz, Lukasz and Metekol, Seda and Kramer, Markus and John, Lisa and Kargarpour, Zahra and Aykara, Iris and Weber, Peter and Anderle, Karolina and Kiener, Hans Peter and Bonelli, Michael and Mrak, Daniel and Aletaha, Daniel and El-Gazzar, Ahmed and Gompelmann, Daniela and Idzko, Marco and Lechner-Radner, Helga},
  title = {Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4834},
  doi = {10.3390/jcm15124834}
}
Kostenlos starten →